Thursday, January 30, 2014

Orthopedic Devices Market Expected to Reach USD 41.2 Billion Globally in 2019


Orthopedic Devices Market Expected to Reach USD 41.2 Billion Globally in 2019. Growing elderly population combined with the rise in risk for osteoporosis, osteoarthritis, injuries and obesity, contribute to the growth of this market particularly in emerging economies of the Middle East, and the Asian countries such as China and India. Technological advancements such as bio-absorbable implants coupled with increase in the success rate of these implants and fixators in the emerging market, will also drive growth in this sector.

Full Press Release Follows.

SOURCE: Transparency Market Research | Web: http://www.transparencymarketresearch.com/


NEW YORK, January 30, 2014 /PRNewswire/ --According to a new market report published by Transparency Market Research, "Orthopedic Devices Market (Hip, Knee, Spine, Shoulder, Elbow, Foot and Ankle, Craniomaxillofacial and Other Extremities ) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019,” the global orthopedic devices market was valued at USD 29.2 billion in 2012 and is expected to grow at a CAGR of 4.9% from 2013 to 2019, to reach an estimated value of USD 41.2 billion in 2019.
Browse Orthopedic Devices Market Report with Full TOC at http://www.transparencymarketresearch.com/orthopedic-devices-market.html
Orthopedic devices are used to provide or restore stability by placing them within the body's skeleton. These help in correcting the problems associated with the bone and joints such as injuries or deformities. Insertion of these orthopedic devices such as joint implants, internal and external fixators involves surgical procedures which can be minimally invasive. Growing elderly population combined with the rise in risk for osteoporosis, osteoarthritis, injuries and obesity, contribute to the growth of this market particularly in emerging economies of the Middle East, and the Asian countries such as China and India. Furthermore, technological advancements such as bio-absorbable implants coupled with increase in the success rate of these implants and fixators in the emerging market, will serve as an opportunity for investors to invest in.
The global market for orthopedic devices has been studied from the perspective of widely used various orthopedic devices and number of procedures for particular anatomical location. The report provides a detailed analysis of orthopedic devices for hip, knee, shoulder, elbow, foot and ankle, and other extremities. These are further segmented into joint implants, internal fixation devices and external fixation devices. The others extremities segment comprises the market for wrists, digits and hand. The market has also been estimated for spinal orthopedic devices which includes cervical and thoracolumbar spinal implants and the internal fixation devices. Moreover, orthopedic devices for craniomaxillofacial comprises only of internal fixation devices.
In 2012, knee orthopedic devices accounted for the largest share by revenue of the total orthopedic devices market. However, the product recalls caused due to factors such as implant loosening, corrosion, wear, and manufacturing errors are expected to have a major impact on the overall market revenue. Thus, the U.S. and European markets are anticipated to see a decline in growth during the forecast period. The market for hip orthopedic products accounted for the second largest share in 2012. It is estimated that the global market for hip devices will grow at a CAGR of over 5.9% from 2013 to 2019, owing to its high incidence rate of hip fractures and demand for hip replacement procedures.
The report also provides market estimations for orthopedic consumables during the forecast period of 2013 to 2019. This market has been segmented as anchors and staples. Anchors form a major share of the total orthopedic consumables market contributing to around 80% of the market share in 2012. The overall orthopedic consumables market is expected to grow to reach a value of USD 457 million by 2019.
Geographically, North America dominated the global market for orthopedic devices in terms of revenue generation and is expected to maintain its position throughout the forecast period. The adoption of bio absorbable implants, growing elderly population and rise in incidences of osteoporosis, osteoarthritis, and obesity in the U.S., consequently leading to various types of fractures, is expected to contribute to the leadership of the North American market. Europe was the second largest regional market for orthopedic devices in 2012, owing to the increased demand for drug eluting stents and infusion pumps. Asia-Pacific is expected to be the fastest growing region in the global orthopedic devices market from 2013 to 2019.
The global hip and knee orthopedic devices market is dominated by major players including Depuy Synthes, Zimmer and Stryker, while the overall spinal devices market is dominated by Medtronic, Depuy, Styrker and NuVasive.
The global orthopedic devices market is segmented as follows:
Orthopedic Devices Market, by Anatomical Location
▪    Hip
◦                      Hip Joint Implants
▪                                        Metal on metal
▪                                        Ceramic on ceramic
▪                                        Ceramic on polyethylene
◦                      Hip Internal Fixation Devices
▪                                        Nails/Rods
▪                                        Plates
▪                                        Screws
▪                                        Wires
◦                      Hip External Fixation Devices
▪                                        Frames
▪                                        Pins
▪    Knee
◦                      Knee Joint Implants
▪                                        Posterior stabilization design
▪                                        Cruciate retaining design
▪                                        Uni-compartmental knee implant
◦                      Knee Internal Fixation Devices
▪                                        Pins
▪                                        Plates
▪                                        Screws
▪                                        Wires
◦                      Knee External Fixation Devices
▪                                        Frames
▪                                        Clamps
▪                                        Pins
▪    Spine
◦                      Spine Joint Implants
▪                                        Cervical Implants
▪                                        Thoracolumbar Implants
◦                      Spine Internal Fixation Devices
▪                                        Nails/Rods
▪                                        Plates
▪                                        Screws
▪                                        Wires
▪    Shoulder
◦                      Shoulder Joint Implants
▪                                        Total joint implant
▪                                        Resurfacing
◦                      Shoulder Internal Fixation Devices
▪                                        Pins
▪                                        Nails/Rods
▪                                        Plates
▪                                        Screws
▪                                        Wires
◦                      Shoulder External Fixation devices
▪                                        Frames
▪                                        Clamps
▪                                        Pins
▪    Elbow
◦                      Elbow Joint Implants
◦                      Elbow Internal Fixation Devices
▪                                        Pins
▪                                        Plates
▪                                        Screws
▪                                        Wires
◦                      Elbow External Fixation Devices
▪                                        Frames
▪                                        Clamps
▪                                        Pins
▪    Foot and Ankle
◦                      Foot and Ankle Joint Implants
◦                      Foot and Ankle Internal Fixation Devices
▪                                        Pins
▪                                        Nail/Rods
▪                                        Plates
▪                                        Screws
▪                                        Wires
◦                      Foot and Ankle External Fixation Devices
▪                                        Frames
▪                                        Clamps
▪                                        Pins
▪    Cranio-Maxillofacial (CMF)
◦                      CMF Internal Fixation Devices
▪                                        Mesh
▪                                        Plates
▪                                        Screws
▪                                        Wires
▪    Other Extremities
◦                      Joint Implants
◦                      Internal Fixation Devices
▪                                        Pins
▪                                        Nails/Rods
▪                                        Plates
▪                                        Wires
▪                                        Screws
◦                      External Fixation
▪                                        Frames
▪                                        Pins        

Orthopedic Devices Market, by Consumables
▪    Anchors
◦                      Suture anchors
◦                      Metallic anchors
▪    Staples

Orthopedic Devices Market, by Geography
▪    North America
▪    Europe
▪    Asia-Pacific
▪    Rest of the World (RoW)

Browse all Medical Devices Market Research Reports @ http://www.transparencymarketresearch.com/medical-devices-market-reports-6.html
About Us
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact 
Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com


Wednesday, January 15, 2014

Medical Patent News: New Class of RNA Therapeutics

MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics. VSRNAs [very small noncoding double stranded RNA molecules] described in this Application exert a preferential biological activity on certain tumor cells to achieve targeted tumor cell death, while showing no effect on normal, non-transformed cells
Press Release Follows.
SOURCE: MultiCell Technologies, Inc. 
WOONSOCKET, R.I., Jan. 15, 2014 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB) has filed a U.S. provisional patent application concerning composition of matter, biological targets, mechanism of action, methods and formulations to achieve targeted tumor cell death. 
This patent application describes a novel class of very small noncoding double stranded RNA molecules (VSRNAs) which interfere with the basic homeostatic cellular processes in tumor cells. VSRNAs are of molecular size less than 10 bps, yet are surprisingly capable in their ability to affect the metabolism, viability and proliferative rate of tumor cells consistent with a mechanism of action that bypasses completely, or in part, the canonical known pathways and steps of RNA recognition and RNA interference.  
In contrast to other species of RNAs, VSRNAs can induce cell death through pyroptosis; a specific biological process that also involves pro-inflammatory cytokine production.  Pyroptosis results from the capability of VSRNAs to suppress or modify the amount of mRNA expressing various endogenous genes linked to the metabolism, proliferation and viability of cells, thus inducing a state of cellular stress that results in deployment of mediators of innate immunity.  VSRNAs described in this Application exert a preferential biological activity on certain tumor cells while showing no effect on normal, non-transformed cells.  
Since cancer cells are highly metabolically active, they are more reliant on key housekeeping molecules for survival as opposed to normal cells.  Through mobilization of stress pathways and non-canonical RNA sensors, VSRNAs have demonstrated the capability of activating the NF-kB pathway and Ca2+ release, resulting in (1) secretion of pre-formed cytokines stored in cell vesicles, and (2) de novo synthesis of cytokines and chemokines.  VSRNAs can be formulated, attached or integrated within delivery vehicles that target or express selectively their payload in desired cell types resulting in both immediate and long-term therapeutic effects against cancer.
MultiCell is evaluating MCT-485, a VSRNA, in animal models of hepatocellular carcinoma.  Hepatocellular carcinoma is the most common form of primary liver cancer, and is a leading cause of cancer death worldwide.  Over 1 million cases of hepatocellular carcinoma are reported annually.  Current approaches for treatment of hepatocellular carcinoma are of limited efficacy.  MCT-485, possessing both oncolytic and immune activating properties, could be superior to currently marketed therapies by providing a more robust activation of immunity, and a more global and longer lasting anti-tumor effect.  Additionally, due to its unique mechanism of action, MCT-485 could prove effective in killing other types of cancers.  MultiCell plans to initiate similar studies in relevant in vitro and animal models for other major cancers.
About MCT-485
MultiCell Technologies' MCT-485 is a very small noncoding double stranded RNA (VSRNA), and the first of a family of prospective cancer therapeutics.  MultiCell owns rights to several issued U.S. and foreign patents and patent applications related to MCT-485 and other RNAs.
About MultiCell Technologies, Inc.
MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease and cancer.  For more information about MultiCell Technologies, please visit http://www.multicelltech.com.
Caution Regarding Forward-Looking Statements
Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act").  These statements are often, but not always, made through the use of words or phrases such as "believe", "will", "expect", "anticipate", "estimate", "intend", "plan", "forecast", "could", and "would". MultiCell bases these forward- looking statements on current expectations about future events.  They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement.  Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our products as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations.  For additional information about risks and uncertainties MultiCell faces, see documents that MultiCell files with the Securities and Exchange Commission, including MultiCell's report on Form 10-K for the fiscal year ended November 30, 2012, and all of MultiCell's quarterly and other periodic SEC filings.  MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.
SOURCE MultiCell Technologies, Inc.
CONTACT: MultiCell Technologies, Inc., W. Gerald Newmin, Chairman & CEO, (401) 762-0045, MCETInvestor@MultiCelltech.com


Tuesday, January 7, 2014

Financing News: Bellicum Pharmaceuticals Raises $34.4 Million in Series B

Bellicum Pharmaceuticals Raises $34.4 Million in a Series B Financing
Funds Will Expand Clinical Development of Company's Controlled Cellular Immunotherapies
Full Press Release Below.
SOURCE: Bellicum Pharmaceuticals

HOUSTON, Jan. 7, 2014 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. announced today that it has completed a second and final closing of its Series B financing, securing an additional $14.7 million and bringing the total raised in the round to $34.4 million. Current investors provided the additional funding, including AVG Ventures and Remeditex Ventures.
The funding will be used to expand clinical development of Bellicum's lead cellular immunotherapy product candidates.
"Bellicum is well positioned within the highly promising field of cellular immunotherapy with a technology that provides control over cells after they have been administered to the patient," said Bellicum CEO Tom Farrell. "This funding will be used to advance our two clinical programs in leukemia/lymphoma and prostate cancer, and launch studies in additional indications where there is urgent need for safer and more effective cell therapies."
Bellicum's two lead clinical development programs utilize the Company's unique ability to control cell therapies once inside the body. BPX-501 T cells contain the Company's CaspaCIDe™ gene "safety switch," enabling physicians to eliminate transplanted cells in the event they become harmful to the patient. The product is being evaluated in a Phase I/II study to reduce or eliminate Graft versus Host Disease in cancer patients undergoing hematopoietic stem cell transplant.
BPX-201 dendritic cells contain the Company's DeCIDe ® gene "on switch," which enables physicians to strategically target immune activation for a more potent anti-tumor effect. It is being evaluated in a Phase I clinical trial in patients with metastatic castrate-resistant prostate cancer.
About Bellicum Pharmaceuticals
Bellicum is dedicated to developing safer and more effective cell therapies to treat cancers and other serious, life-threatening diseases. The Company's cell therapies are engineered with a gene "switch" that enables physicians to activate or eliminate cells once inside the body to improve safety and efficacy. Bellicum is advancing clinical programs in cellular transplants to reduce or eliminate Graft versus Host Disease, and in prostate cancer with a potentially more potent immunotherapy. For more information please visit www.bellicum.com
SOURCE Bellicum Pharmaceuticals, Inc.
CONTACT: Brad Miles, 646-513-3125, bmiles@bmccommunications.com, or Amy Bonanno, 646-513-3117, abonanno@bmccommunications.com